Diabetic Retinopathy Treatment
Diabetic Retinopathy Treatment
The treatment of diabetic retinopathy is layered, and the layers are ordered by what each can change. The first layer belongs to the diabetes rather than the eye: glucose, blood pressure and lipid control slow the vessel disease at every stage, and no eye treatment works as well as it should without them. The second layer treats swelling of the macula — injections of anti-VEGF medication into the eye, which reduce the swelling, and focal or grid laser, which seals specific leaking points when the centre itself is not involved. The third layer treats proliferative disease: panretinal scatter laser, which makes fragile new vessels shrink and disappear by treating the deprived retina that drove them to grow, protecting the eye from bleeding and traction. The fourth layer is surgery — vitrectomy — for blood that will not clear, membranes that pull on the retina, and the tractional detachments that proliferative disease can produce. What unites the layers is a principle stated at the outset: the aim of all of it is to protect and preserve the sight the patient still has. Macular swelling caught early often improves; tissue already lost to closure, bleed or scar does not return. That is why treatment is offered at stages the patient cannot feel, and why the schedule matters as much as any single procedure.
The foundation: glucose, blood pressure and lipids
Before any eye treatment is discussed, the ground it stands on is set by three numbers:
- Glucose control, measured over years. HbA1c averaged over time is what the vessels respond to. Tight control does not reverse existing damage, but it slows progression measurably — and it is the precondition that every other treatment assumes.
- Blood pressure. Raised pressure accelerates retinal damage independently of glucose and worsens the outlook of every stage. It is treated as part of the eye plan, not adjacent to it.
- Lipids. The hard, fatty exudates that damage the macula travel with lipid levels, and their control reduces one of the ingredients of macular damage.
What the foundation is and is not. It is not a substitute for treatment — an eye with macular swelling or new vessels is treated, whatever the readings. But it is the reason some eyes never reach those stages, and the reason treated eyes hold their ground. Control is the treatment that runs through all the others.
Injections for macular swelling: what anti-VEGF treatment does
When the macula is swollen and the centre is involved, the usual first treatment is a medication injected into the eye:
- What the drug does. The deprived retina produces a signal (VEGF) that makes vessels leak and drives abnormal growth. Anti-VEGF medication blocks the signal, and the swelling it causes falls.
- What the injection involves. The eye is numbed with drops, the medication is placed into the vitreous with a fine needle in minutes, and the patient goes home the same day. The procedure is briefer than the preparation around it.
- What the schedule looks like. Treatment begins with a course of injections and continues according to what the macular measurements do — the OCT number at each visit decides the next step rather than the calendar alone.
What results to expect, honestly. Swelling caught early often improves, and the treatments are judged on measured macular change and reading vision over months. Eyes in which the swelling has been present a long time, or the centre has been damaged, improve less. The schedule is demanding — and it is the price of holding the centre.
Laser for swelling: focal and grid treatment
Laser has treated macular edema for decades, and it retains a specific place beside the injections:
- What it is used for. Focal laser seals discrete leaking points around the macula; grid laser treats wider areas of diffuse leakage — both are used where the swelling sits away from the very centre or alongside injection treatment.
- What the session involves. Drops numb the eye, a lens is placed on its surface, and a session of precisely placed burns takes minutes. It is an outpatient treatment, and the vision is usually blurred for hours afterwards.
- What it achieves. The aim is not to sharpen the vision directly but to stop the leaking — to stabilise the macula and reduce the fluid that erodes it over time.
How laser and injections are combined. In many eyes the two are sequenced rather than chosen: injections reduce the swelling, laser closes the leaks that persist, and the measurements decide the order. The plan is written around the macula’s behaviour, not around a preference for either tool.
Scatter laser for new vessels: panretinal photocoagulation
Where new vessels have grown — or are about to — the laser is turned to a different task altogether:
- The logic is indirect and worth understanding. New vessels grow because large areas of peripheral retina are starved of oxygen. Treating those areas with scattered burns removes the demand, and the new vessels shrink and disappear — the treatment works on the cause rather than on the vessels themselves.
- What the treatment involves. Sessions of scattered laser spots across the peripheral retina, performed as an outpatient over one or more visits, with drops and a lens as for focal treatment.
- What it trades. Scatter laser protects the eye from bleeding and traction — the complications that destroy vision — at the cost of some peripheral and night vision. That trade is discussed before it is made, because it is the central decision of this stage.
Why it is offered before anything has bled. The stage at which scatter laser works best is the one at which the patient notices nothing. The treatment is prophylactic in effect: its success is measured in bleeds and detachments that never happen.
Vitrectomy: blood that will not clear, membranes and traction
Surgery enters the plan when the disease has produced problems no laser or injection can reach:
- Blood that obscures the retina. A bleed that will not clear on its own is removed, which restores the view both for the patient and for treating the rest of the eye.
- Membranes that pull. Scar tissue contracted over the retina tugs at it and distorts or detaches it; the operation removes what is pulling and settles the retina back — the same principles as repairing a retinal detachment, here driven by diabetes rather than by a tear.
- What the operation involves. The vitreous gel is removed through small openings, the retina is freed and stabilised, and laser is applied from inside the eye during the same procedure; a gas or oil bubble may hold things in place afterwards.
What surgery can and cannot do. It can clear, release and reattach — mechanical tasks, usually achievable. It cannot restore function in retinal tissue that the disease has already taken. That is why the operation is discussed with the patient in terms of protecting and rescuing what remains, before rather than after.
What treatment actually involves: visits, injections and monitoring
Most of the treatment of this disease is not any single procedure; it is the schedule built around them:
- Injections come in courses, not singles. An eye treated for macular swelling is seen repeatedly over months, with the OCT measurement deciding the pace. Patients plan around the series rather than around one appointment.
- Monitoring continues whatever is done. Laser, injections and surgery all live inside the same framework of graded review — each eye keeps its interval, and the grades are compared visit by visit.
- The other eye is treated as part of the plan. An eye that has needed treatment obliges closer watching of its partner, which shares the same vessels and much of the same course.
What the patient controls. The measurements and the procedures are ours; the glucose, pressure and lipid control, and the attendance that keeps the schedule intact, are the patient’s. In this disease that division is unusually even, and the outcome depends on both halves being kept.